Guideline: Screening for prostate cancer (Republic of Cyprus): Difference between revisions
m (Update categories.) |
m (Update categories.) |
||
| Line 25: | Line 25: | ||
<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span> | <span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span> | ||
<span style="display:none">isPracticeGuideline</span> | <span style="display:none">isPracticeGuideline</span> | ||
<span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | |||
<span style="display:none">hasCancerType::C00-C97: All cancer types</span> | |||
Revision as of 11:22, 6 December 2025
Go back to Republic of Cyprus page
Primary purpose: To outline the risk assessment and recommended procedures for PSA testing to detect prostate cancer.
Sponsor, manager or home institution: Ministry of Health and Health Insurance Organization.
Type of information: This guideline provides risk percentages for prostate cancer based on PSA levels, along with screening recommendations considering age, race, family history, and other factors affecting PSA results. It also includes guidance on when to pursue further diagnostic procedures and highlights the importance of individualized patient-physician discussions. diagnosis, medical procedures, age, screening, check-up examinations.
Cancer Areas of Interest: C60-C63: Male genitalia cancer. Click here to learn more.
Access to information: Click here to access.